QR kód

Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma

High-grade neuroendocrine carcinoma (NEC) of the rectum is a rare and aggressive malignancy, with limited treatment options and a poor prognosis. We report the successful off-label use of the PARP inhibitor talazoparib in a patient with metastatic, germline BRCA2-mutated rectal NEC who had a contrai...

Celý popis

Uloženo v:
Hlavní autoři: Milan Khealani, Byoung Uk Park, Robben Schat, Emmanuel S. Antonarakis, Arjun Gupta
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2025-12-01
Edice:Frontiers in Oncology
Témata:
rectal neuroendocrine carcinoma
gBRCA2 mutation
talazoparib
PARP inhibitor
case report
On-line přístup:https://www.frontiersin.org/articles/10.3389/fonc.2025.1705579/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky